-
Mashup Score: 0Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith - 6 month(s) ago
Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study’s secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad - 6 month(s) ago
Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Deep PSA response following the addition of darolutamide to ADT and docetaxel in #ARASENS. Fred Saad, MD, FRCS @chumontreal and @zklaassen_md @GACancerCenter discuss the trial's transformative impact on #ProstateCancer treatment. #WatchNow > https://t.co/az1qfirLcO https://t.co/rWxpZInWAb
-
-
Mashup Score: 0Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith - 7 month(s) ago
Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study’s secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Exploring darolutamide's impact on time to pain progression based on disease volume in #ARASENS. Join Matthew Smith @MGHMedicine and @CaPsurvivorship @DanaFarber in discussing the implications of this study and how to incorporate this data into practice > https://t.co/sxMBMZm6M5 https://t.co/ou3Ha2JMGM
-
-
Mashup Score: 0Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith - 8 month(s) ago
Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study’s secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Exploring darolutamide's impact on time to pain progression based on disease volume in #ARASENS. Join Matthew Smith @MGHMedicine and @CaPsurvivorship @DanaFarber in discussing the implications of this study and how to incorporate this data into practice > https://t.co/sxMBMZmEBD https://t.co/WkODPyD2Yd
-
-
Mashup Score: 2Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad - 8 month(s) ago
Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Deep PSA response following the addition of darolutamide to ADT and docetaxel in #ARASENS. Fred Saad, MD, FRCS @chumontreal and @zklaassen_md @GACancerCenter discuss the trial's transformative impact on #ProstateCancer treatment. #WatchNow > https://t.co/az1qfirLcO https://t.co/6zS5QZY4Wi
-
-
Mashup Score: 0Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the ARASENS Trial - Karim Fizazi - 9 month(s) ago
Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of darolutamide in combination with ADT and docetaxel by disease volume and disease risk in the #ARASENS trial. @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/UTSvewcfNi @Bayer https://t.co/1NYTpIsOIE
-
-
Mashup Score: 3Deep PSA Response Following Addition of Darolutamide to ADT and Docetaxel in ARASENS - Fred Saad - 9 month(s) ago
Zach Klaassen hosts a discussion with Fred Saad about the ARASENS data and its transformative impact on prostate cancer treatment. This conversation primarily explores the correlation between a rapid, deep, and durable PSA response and excellent patient outcomes. Dr. Saad underlines the biological significance of a decline in PSA, noting how patients who achieve undetectable PSA levels…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Deep PSA response following the addition of darolutamide to ADT and docetaxel in #ARASENS. Fred Saad, MD, FRCS @chumontreal and @zklaassen_md @GACancerCenter discuss the trial's transformative impact on #ProstateCancer treatment. #WatchNow > https://t.co/az1qfisj2m https://t.co/rDbxtpgfkq
-
-
Mashup Score: 0Exploring Darolutamide's Impact on Time to Pain Progression Based on Disease Volume in the ARASENS Study - Matthew Smith - 10 month(s) ago
Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study’s secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Exploring darolutamide's impact on time to pain progression based on disease volume in #ARASENS. Join Matthew Smith @MGHMedicine and @CaPsurvivorship @DanaFarber in discussing the implications of this study and how to incorporate this data into practice > https://t.co/sxMBMZm6M5 https://t.co/qswyHZBYYz
-
-
Mashup Score: 0Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the ARASENS Trial - Karim Fizazi - 10 month(s) ago
Alicia Morgans and Karim Fizazi discuss the ARASENS data and how it relates to whether patients with high-volume or low-volume metastatic castration-sensitive disease should be treated differently with systemic treatments. They explain that while historically, CHAARTED showed benefits in high-volume but not low-volume disease, STAMPEDE showed benefits for all patients regardless of volume. The…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Efficacy and safety of darolutamide in combination with ADT and docetaxel by disease volume and disease risk in the #ARASENS trial. @fizazi_karim @GustaveRoussy joins @CaPsurvivorship @DanaFarber to discuss on UroToday > https://t.co/UTSvewcfNi @Bayer https://t.co/BlKrB33rZ8
-
-
Mashup Score: 0ASCO 2023: Efficacy and Safety of Darolutamide in Chinese Patients with mHSPC: A Subpopulation Analysis of the Phase 3 ARASENS Study - 11 month(s) ago
ASCO 2023, prostate cancer, ARASENS study, metastatic hormone-sensitive prostate cancer (mHSPC), ARASENS treatment for chinese population with prostate cancer, docetaxel, efficacy and safety of darolutamide in the Chinese subpopulation of ARASENS.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
#ARASENS subpopulation of Chinese patients with #mHSPC, darolutamide + ADT + docetaxel showed favorable efficacy and safety vs placebo + ADT + docetaxel. Presented by Shanshan Wang, PhD. #ASCO23 written coverage by @zklaassen_md on UroToday > https://t.co/CPDJg35bmw @ASCO https://t.co/8P7HHmPiOd
-
Exploring darolutamide's impact on time to pain progression based on disease volume in #ARASENS. Join Matthew Smith @MGHMedicine and @CaPsurvivorship @DanaFarber in discussing the implications of this study and how to incorporate this data into practice > https://t.co/sxMBMZm6M5 https://t.co/YLbdtSVlyf